natgillin/translations-raw huggingface dataset:
Process according to anyone of the preceding Claims, in which the sulphuric acid that is added to the aqueous thorium salt solution is 36N acid. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da sumporna kiselina koja se dodaje u vodenu otopinu torijeve soli je kiselina 36N.
Process according to Claim 11, in which the flocculation of the coprecipitate is facilitated by the addition of a flocculant. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da se flokulacija koprecipitata olakšava dodavanjem flokulanta.
Process according to Claim 13, in which the coprecipitate is washed by carrying out one or more repulping operations on this coprecipitate using the weakly acid aqueous solution, each repulping operation being followed by a sedimentation. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time, da se koprecipitat ispire jednom ili više operacija repulpacije na tom koprecipitatu upotrebom slabo kisele vodene otopina, a nakon svake operacije repulpacije slijedi postupak taloženja.
An isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide is selected from the group consisting of peptides comprising the amino acid sequence of SEQ ID NO: 30, 19, 22, 34, or 358. 
Izolirani peptid od manje od 15 aminokiselina koja može inducirati citotoksične T-stanice, naznačen time što se navedeni peptid bira iz skupine koju čine peptidi koji sadrže aminokiselinski slijed SEQ ID NO: 30, 19, 22, 34 ili 358.
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 19, 22, 34, and 358, in which 1 or 2 amino acids are substituted, deleted, or added, wherein said peptide induces cytotoxic T lymphocytes specific to a cell expressing CDH3. 
Peptid od manje od 15 aminokiselina koja može inducirati citotoksične T-stanice, gdje navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34, te 358, u kojem su 1 ili 2 aminokiseline zamijenjene, izbačene ili dodane, naznačen time što navedeni peptid inducira citotoksične T-limfocite specifične za stanicu koja eksprimira CDH3.
The peptide having cytotoxic T cell inducibility of claim 2, wherein said peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 19, 22, 34 and 358, in which 1 or 2 amino acids are substituted or added, wherein said peptide induces cytotoxic T lymphocytes specific to a cell expressing CDH3. 
Peptid koji može inducirati citotoksične T-stanice u skladu s patentnim zahtjevom 2, gdje se navedeni peptid sastoji od aminokiselinskog slijeda kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34 i 358, u kojem 1 ili 2 aminokiseline su zamijenjen ili dodan, naznačen time što navedeni peptid inducira citotoksične T-limfocite specifične za stanicu koja eksprimira CDH3.
An isolated peptide consisting of the amino acid sequence of SEQ ID NO: 30, 19, 22, 34 or 358. 
Izolirani peptid, naznačen time što se sastoji od aminokiselinskog slijeda SEQ ID NO: 30, 19, 22, 34 ili 358.
The exosome of claim 8, wherein the HLA antigen is HLA-A2402. 
Egzosom u skladu s patentnim zahtjevom 8, naznačen time što je HLA antigen HLA-A2402.
An in vitro method of inducing a cytotoxic T cell by contacting a T cell with a peptide of any one of claims 1 to 7. 
Postupak in vitro induciranja citotoksične T-stanice, naznačen time što se sastoji u stavljanju u kontakt T-stanice s peptidom u skladu s bilo kojim od patentnih zahtjeva 1 do 7.
A vaccine for use in inhibiting proliferation of a cell expressing the gene of SEQ ID NO: 1, wherein the vaccine comprises a peptide of any one of claims 1 to 7 as an active ingredient. 
Cjepivo namijenjeno upotrebi u inhibiranju proliferacije stanice koja eksprimira gen iz SEQ ID NO: 1, naznačeno time što cjepivo sadrži peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 7 kao aktivni sastojak.
The pharmaceutical composition of claim 8, the use of claim 9, 19 or 22 or the vaccine of claim 19 or 21, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer, diffused type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, upotreba u skladu s patentnim zahtjevom 9, 19 ili 22, ili cjepivo u skladu s patentnim zahtjevom 19 ili 21, naznačeni time što rak se bira iz skupine koju čine rak mokraćnog mjehura, rak dojke, rak vrata maternice, kolangiocelularni karcinom, CML, rak debelog crijeva, endometrioza, rak jednjaka, rak želuca, difuzni tip raka želuca, rak jetre, NSCLC, limfom, osteosarkom, rak jajnika, rak gušterače, rak prostate, karcinom bubrega, SCLC, tumor mekog tkiva i tumor testisa.
identifying the peptide of which CTL inducibility is the same as or higher than the one of a peptide consisting of the original amino acid sequence. 
identificiranja peptida čija je CTL inducibilnost ista kao ili veća nego za peptid koji se sastoji od izvornog aminokiselinskog slijeda.
A supporting assembly for supporting a linen washing machine drum, characterized in that said supporting assembly comprises a multiple-lobe construction made of a fiberglass reinforced plastics material, constituted by a plurality of radially extending arms integrally formed with a central body and that said supporting assembly comprises a metal shaft co-molded in said central body. 
Nosač bubnja perilice rublja, naznačen time da se konstrukcija spomenutog nosača sastoji od više režnjeva izrađenih od plastičnog materijala ojačanog staklenim vlaknima, s krakovima koji se pružaju zrakasto i čine jedinstvenu cjelinu sa središnjim tijelom i da spomenuti nosač ima jednu metalnu osovinu koja je kalupno lijevana u spomenuto središnje tijelo.
A supporting assembly, according to claim 1, characterized in that said multiple-lobe construction is made by molding a fiberglass reinforced plastics material constituted by glass fibers embedded in a thermoplastic material such as polyamide. 
Nosač u skladu sa zahtjevom 1, naznačen time da je spomenuta konstrukcija od više režnjeva izrađena lijevanjem plastičnog materijala koji sačinjavaju staklena vlakna ugrađena u neki termoplastični materijal poput poliamida.
A supporting assembly, according to claim 1, characterized in that said fiberglass reinforced plastics material comprises glass fibers in a rate up to 65% and a plastic material rate corresponding to the remaining part. 
Nosač u skladu sa zahtjevom 1, naznačen time da spomenuti plastični materijal ojačan staklenim vlaknima sadržava ta vlakna u omjeru do 65% dok preostali udio odgovara plastičnom materijalu.
a first QAM mapper (306-1) configured to map the cell words of the Layer 1 signaling data into constellation values; and 
prvi QAM maper (306-L1) konfiguriran za mapiranje demultipleksirnog signalnog podatka razine 1 u konstelacijske vrijednosti;
An isolated antibody or antigen-binding fragment thereof which can specifically bind to Sp35 and can antagonize Sp35, wherein the antibody or fragment thereof is selected from the group consisting of: 
Izolirano antitijelo ili antigen vezujući fragment istog koji se može specifično vezati na Sp35 i koji može antagonizirati Sp35, pri čemu je antitijelo ili fragment istog odabrano iz skupine koja se sastoji od:
an antibody or antigen-binding fragment thereof comprising a VH and a VL, wherein the VH comprises SEQ ID NO:170 and the VL comprises SEQ ID NO:283. 
antitijela ili antigen vezujućeg fragmenta istog koji sadržava VH i VL, pri čemu VH sadržava SEQ ID NO:170 a VL sadržava SEQ ID NO:283.
The isolated Sp35 antibody or antigen-binding fragment thereof according to claim 1 or 2, for use in treating traumatic brain injury, spinal cord injury, or optic nerve injury. 
Izolirano Sp35 antitijelo ili antigen vezujući fragment istog u skladu sa zahtjevom 1 ili 2 za upotrebu u liječenju traumatske ozljede mozga, ozljede hrptene moždine ili ozljede optičkog živca.
Use of the isolated Sp35 antibody or antigen-binding fragment thereof according to claim 1 or 2 for the manufacture of a medicament for treating multiple sclerosis. 
Upotreba izoliranog Sp35 antitijela ili antigen vezujućeg fragmenta istog u skladu sa zahtjevom 1 ili 2 za proizvodnju medikamenta za liječenje multiple skleroze.
An in vitro method of inhibiting signal transduction by NgR1, the method comprising contacting the NgR1 with an effective amount of the isolated Sp35 antibody or antigen-binding fragment according to claim 1 or 2. 
In vitro metoda inhibiranja transdukcije signala pomoću NgR1, metoda koja se sastoji od kontaktiranja NgR1 učinkovitom količinom izoliranog Sp35 antitijela ili antigen vezujućeg fragmenta u skladu sa zahtjevom 1 ili 2.
are two methylene groups bound to different carbon atoms of the cycloalkyl ring, wherein the methylene groups or the CH2-CH-(CH2)2 group are bound to carbon atoms of the cycloalkyl ring and form an adamantane system of the formula wherein the oxygen atom can be bound to any secondary or tertiary carbon atom, or R6 together with R11 and the N atom form a (C3-C8)heterocycloalkyl which is connected as a spirocyclic ring system to the cycloalkyl residue; 
su dvije metilenske skupine, vezane na različite atome ugljika u cikloalkilnom prstenu, gdje su metilenske skupine ili skupina CH2-CH-(CH2)2 vezane na atome ugljika u cikloalkilnom prstenu i tvore adamantanski sustav formule [image], gdje atom kisika može biti vezan na bilo koji sekundarni ili tercijarni atom ugljika, ili R6, zajedno s R11 i N atomom, tvore (C3-C8)heterocikloalkil, koji je vezan kao spirociklički prstenasti sustav na cikloalkilni ostatak;
wherein the bicyclic ring system or adamantane system or the (C3-C8)heterocycloalkyl containing ring system is unsubstituted or optionally substituted by R9; 
gdje biciklički prstenasti sustav ili adamantanski sustav ili prstenasti sustav koji sadrži (C3-C8)heterocikloalkil nije supstituiran ili je izborno supstituiran s R9;
or R11 and R12, together with the N-atom to which they are attached, form a (C3-C8) heterocycloalkyl; 
ili i R12, zajedno s N atomom ne kojeg su vezani, tvore (C3-C8) heterocikloalkil;
A compound according to one of claims 1 to 14, wherin R9 is allyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethylene, isopropyloxymethylene, tetrahydrofuranyl, tetrahydropyranyl, phenyl or benzyl. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je R9 alil, metil, etil, propil, izopropil, butil, izobutil, ciklopropil, ciklobutil, ciklopentil, ciklopropilmetilen, izopropiloksimetilen, tetrahidrofuranil, tetrahidropiranil, fenil ili benzil.
A compound according to one of claims 1 to 18, wherein R6 together with R11 and the N atom form a (C3-C8)heterocycloalkyl which is connected as a spirocyclic system to the cycloalkyl residue; 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 18, naznačen time što R6, zajedno s R11 i N atomom, tvore (C3-C8)heterocikloalkil, koji je vezan kao spirociklički sustav na cikloalkilni ostatak;
A computer program loadable into the memory of the computer system of claim 5, comprising software code portions for performing, when said program is run on the computer system, the steps of the method as claimed in claims 1 to 4. 
Računalni program koji se može unijeti u memoriju računalnog sustava iz patentnog zahtjeva 5, obuhvaća dijelove koda programa za izvođenje, kad se navedeni program izvodi na računalnom sustavu, koraka metode u skladu s patentnim zahtjevima 1 do 4.
contacting the antigen presenting cell of step (iii) with a T cell to evaluate the ability of the peptide to simulate the T cell; and 
stavljanja u kontakt sa stanicama koje prezentiraju antigen iz koraka (iii) s T-stanice kako bi se procijenila sposobnost peptida da stimulira T-stanice; i
The monoclonal antibody or use of any preceding claim, wherein said fragment is selected from the group consisting of a Fab fragment, an F(ab')2 fragment, an Fv fragment, and a single-chain Fv fragment. 
Antitijelo za uporabu prema Patentnom zahtjevu 7, naznačeno time, što je spomenuti fragment izabran iz grupe koju čine Fab fragment, F(ab')2 fragment, Fv fragment i jednolančani Fv fragment.
The anti-CD40 monoclonal antibody or use of any of claims 1-6, wherein said fragment is selected from the group consisting of a Fab fragment, an F(ab')2 fragment, an Fv fragment, and a single-chain Fv fragment. 
Antitijelo za uporabu prema Patentnom zahtjevu 7, naznačeno time, što je spomenuti fragment izabran iz grupe koju čine Fab fragment, F(ab')2 fragment, Fv fragment i jednolančani Fv fragment.
A transmitter of transmitting a broadcasting signal to a receiver, comprising: means (102) for encoding Physical Layer Pipe (PLP) data for carrying at least one service and Layer-1 (L1) signaling data for signaling the PLP data; 
sredstvo (102) za kodiranje podatka cijevi fizičke razine, PLP, za prijenos najmanje jednog servisa; sredstvo (102) za kodiranje signalnog podatka razine 1, L1, za signaliziranje PLP podatka, pri čemu sredstvo (102) za kodiranje signalnog podatak L1 nadalje obuhvaća;
characterized in that it further comprises, means (308-1) for selectively time-interleaving the encoded L1 signaling data by row-column twisted fashion, in which input L1 signaling data cells are serially written into an interleaving memory in a diagonal direction, and serially read out row-wise, wherein the time-interleaving is performed without considering pilot positions, and outputting a Layer-1 (L1) TI, Time Interleaved,block; 
sredstvo (308-1) za selektivno umetanje vremena u kodirani L1 signalni podatak na način prelamanja redova-stupaca, pri čemu način prelamanja redova-stupaca obuhvaća unos u podatkovne stanice signalnog podatka L1 serijski upisanog u memoriju umetanja u dijagonalnom smjeru, i serijsko očitavanje u smjeru redova, bez razmatranja pozicije pilota, i izlaz L1, bloka umetanja vremena, TI;
means (r306-1) for demapping the time-deinterleaved preamble symbols into bits; and means (r303-1) for decoding the bits by a shortened and punctured LDPC(Low Density Parity Check)decoding scheme. 
sredstvo (r303-1) za unutarnje dekodiranje L1 signalnog podatka shemom kodiranja provjere pariteta niske gustoće, LDPC, i sredstvo (r303-1) za vanjsko dekodiranje unutarnje dekodiranog signalnog podatka L1 pomoću sheme kodiranja Bose-Chadhuri-Hocquenghem, BCH;
means (708-0) for time-interleaving the built data slice packet; 
sredstva (708-0) za podatke koji se naizmjenično isprepliću vremenski u izgrađenom paketu podatkovnih komada;
means (r711) for outputting the PLP data from the data slices; 
sredstva (r711) za izlaz paketa podatkovnih komada koji imaju PLP podatke iz podatkovnog komada;
outputting the PLP data from the data slices; 
izlaz paketa podatkovnih komada koji imaju PLP podatke iz podatkovnog komada;
decoding the selectively time-deinterleaved L1 data for a Forward Error Correction, FEC by a Low Density Parity Check, LDPC, decoding scheme; and 
dekodiranje podataka u paketima podatkovnih komada za unaprijedno ispravljanje pogrešaka, FEC pomoću LDPC sheme za dekodiranje; i vanjsko dekodiranje LDPC dekodiranih podataka.
A medicament comprising Allopurinol or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase inhibitor (MKI) therapy. 
Lijek koji sadrži Alopurinol ili njegovu farmaceutski prihvatljivu sol za uporabu u liječenju ili prevenciji Kožne reakcije na rukama i stopalima (Hand Foot Skin Reaction - HFSR) izazvane terapijom multiciljnih inhibitora kinaze (MKI).
A medicament for use according to claims 1 to 5, wherein the medicament comprises from 1-10 % by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof, preferably from 1% to 8 %, more preferably from 2 to 5 % by weight. 
Lijek za uporabu prema patentnim zahtjevima 1 do 5, naznačen time da sadrži od 1-10% masenog udjela alopurinola ili njegove farmaceutski prihvatljive soli, preporučeno od 1% do 8%, te još bolje od 2 do 5% masenog udjela.
a first step of expansion of the stem cells of blood, immediately after they have been taken from the patient, by means of the in-vitro treatment with MCSF in a concentration comprised between 8-15 nM and 
prvi korak širenja matičnih stanica krvi, odmah nakon što su uzete iz pacijenta, pomoću in-vitro tretmana sa MCSF u koncentraciji sadržanoj između 8-15 nM te
a second step of purification of the expanded stem cell. 
drugi korak pročišćavanja proširene matične stanice.
c) expansion of the stem cells of blood purified in step b) by means of the in-vitro treatment with MCSF in a concentration comprised between about 35-55 nM for 24-72 hours. 
širenje matičnih stanica krvi pročišćenih u koraku b) pomoću in-vitro tretmana sa MCSF u koncentraciji sadržanoj između oko 35-55 nM kroz 24-72 sata.
Method as in claim 1, characterized in that the in-vitro treatment of step a) is started not more than 10 minutes after the sample has been taken, advantageously not more than 5 minutes. 
Metoda kao u patentnom zahtjevu 1, naznačena time da in-vitro tretman u koraku a) započinje ne više od 10 minuta nakon uzimanja uzorka, a najbolje ne više od 5 minuta.
Method as in claim 1, wherein said concentration of MCSF in step c) is preferably 50 nM, more preferably 45 nM. 
Metoda kao u patentnom zahtjevu 1, gdje je spomenuta koncentracija MCSF u koraku c) preporučeno 50 nM, te još preporučenije 45 nM.
Pharmaceutical composition comprising the adult stem cells obtained according to the method as defined in any claim from 1 to 8 at a concentration comprised between 90-250x103 cells/ml, preferably 100-120x103 cells/ml, as active principle, together with pharmacologically acceptable adjuvants and/or excipients, said composition being formulated for intravenous injection, for use in the treatment of lesions chosen from the group consisting of cutaneous lesions, lesions to the tendons, to the ligaments, to the bones, to the mucous membranes in mammals, or fractures, of neurological or neurodegenerative pathologies chosen from the group consisting of Cushing's disease, head shaking, Wobbler's syndrome, breathing difficulties, paresis of the limbs in mammals, of acute or chronic inflammatory pathologies chosen from laminitis, periostitis, gastritis, arthrosis, inflammations caused by viral, bacterial, parasite, mycotic agents in mammals, of the syndrome of dilatation-torsion of the stomach in mammals. 
Farmaceutski pripravak koji sadrži odrasle matične stanice dobivene prema metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 u koncentraciji sadržanoj između 90-250×103 stanica/mL, kao aktivnu tvar, zajedno sa farmakološki prihvatljivim adjuvansima i/ili ekscipijensima, pri čemu se spomenuti pripravak formulira za intravenoznu injekciju, za uporabu u liječenju lezija izabranih iz skupine koja sadrži kožne lezije, lezije tetiva, ligamenata, kostiju, mukozne membrane u sisavcima, ili fraktura, neuroloških ili neurodegenerativnih patologija izabranih iz skupine koja se sastoji od Cushingove bolesti, trešnje glave, Wobblerovog sindroma, teškoća s disanjem, pareze udova u sisavcima, akutnih i kroničnih upalnih patologija izabranih iz laminitisa, periostitisa, gastritisa, artroze, upala uzrokovanih virusnim, bakterijskim, parazitskim, mikotskim agensima u sisavcima, sindroma dilatacije-torzije želuca u sisavcima.
Pharmaceutical composition comprising the adult stem cells obtained according to the method as defined in any claim from 1 to 8 at a concentration comprised between 4-40x106 cells/ml, preferentially 7x106 cells/ml, as active principle together with pharmacologically acceptable adjuvants and/or excipients, said composition being formulated for local application, for use in the treatment of lesions chosen from the group consisting of cutaneous lesions, lesions to the tendons, to the ligaments, to the bones, to the mucous membranes in mammals, or fractures, of neurological or neurodegenerative pathologies chosen from the group consisting of Cushing's disease, head shaking, Wobbler's syndrome, breathing difficulties, paresis of the limbs in mammals, of acute or chronic inflammatory pathologies chosen from laminitis, periostitis, gastritis, arthrosis, inflammations caused by viral, bacterial, parasite, mycotic agents in mammals, of the syndrome of dilatation-torsion of the stomach in mammals. 
Farmaceutski pripravak koji sadrži odrasle matične stanice dobivene prema metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 u koncentraciji sadržanoj između 4-40×106 stanica/mL, preporučeno 7×106 stanica/mL, kao aktivnu tvar, zajedno sa farmakološki prihvatljivim adjuvansima i/ili ekscipijensima, pri čemu se spomenuti pripravak formulira za lokalnu primjenu, za uporabu u liječenju lezija izabranih iz skupine koja sadrži kožne lezije, lezije tetiva, ligamenata, kostiju, mukozne membrane u sisavcima, ili fraktura, neuroloških ili neurodegenerativnih patologija izabranih iz skupine koja se sastoji od Cushingove bolesti, trešnje glave, Wobblerovog sindroma, teškoća s disanjem, pareze udova u sisavcima, akutnih i kroničnih upalnih patologija izabranih iz laminitisa, periostitisa, gastritisa, artroze, upala uzrokovanih virusnim, bakterijskim, parazitskim, mikotskim agensima u sisavcima, sindroma dilatacije-torzije želuca u sisavcima.
Composition for use as in claim 10, also comprising an antibiotic as an active principle in a concentration comprised between 5-15 nM, preferably 10 nM. 
Spoj za uporabu kao u patentnom zahtjevu 10, koji također sadrži antibiotik kao aktivnu tvar u koncentraciji sadržanoj između 5-15 nM, preporučeno 10 nM.
Composition for use according to claim 9, wherein said composition comprises adult stem cells obtained at a concentration equal to 150x103 cells/ml and is administered once a week intravenously. 
Pripravak za uporabu prema patentnom zahtjevu 9, pri čemu spomenuti pripravak sadrži odrasle matične stanice dobivene u koncentraciji jednakoj 150×103 stanica/ mL te se administrira intravenozno jednom tjedno.
Crystalline Form A of the hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, characterised in that the crystalline form has an X-ray powder diffraction pattern having at least one specific peak at about 2-theta = 20.7°. 
Kristalni oblik A od hemifumaratne soli od 1-(4-{1-[(E)-4-cikloheksil-3-trifluorometil-benziloksiimino]-etil}-2-etil-benzil)-azetidin-3-karboksilne kiseline, naznačen time, da kristalni oblik ima uzorak difrakcije praha X-zraka koji ima barem jednu specifičnu vršnu vrijednost na oko 2-theta = 20,7°.
Crystalline Form A of the hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid according to any one of Claims 4 to 8, characterised in that the crystalline form has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in Figure 1 below: 
,3 3,268 srednji Kristalni oblik A od hemifumaratne soli od 1-(4-{1-[(E)-4-cikloheksil-3-trifluorometil-benziloksiimino]-etil}-2-etil-benzil)-azetidin-3-karboksilne kiseline prema bilo kojem zahtjevu od 4 do 8, naznačen time, da kristalni oblik ima uzorak difrakcije praha X-zraka uglavnom isti kao što je uzorak difrakcije praha X-zraka prikazan na donjoj Slici 1:
Crystalline Form B of the hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid according to Claim 12, characterised in that the crystalline form has an X-ray powder diffraction pattern having only a specific peak at about 2-theta = 2.7°. 
Kristalni oblik B od hemifumaratne soli od 1-(4-{1-[(E)-4-cikloheksil-3-trifluorometil-benziloksiimino]-etil}-2-etil-benzil)-azetidin-3-karboksilne kiseline, prema zahtjevu 12, naznačen time, da kristalni oblik ima uzorak difrakcije praha X-zraka samo onaj koji ima specifičnu vršnu vrijednost na oko 2-theta = 2,7°.